“不可成药”的堡垒正被一寸寸攻破。5月22日,加科思自主研发的KRAS G12C抑制剂戈来雷塞(商品名:艾瑞凯)正式获批,用于KRAS G12C突变的非小细胞肺癌(NSCLC)二线及以上治疗。得益于剂量优势和安全性优势,市场对此适应症给出近20亿元的销售峰值预测。KRAS,一个大名鼎鼎的不可成药靶点。被发现40年来,直到2013年加州大学教授Kevan Shokat的研究突破,才为后来者提供研发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.